Evidence map›Paper›PMID 33912600›Full record

ReviewFrontiers in cardiovascular medicine2021

Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target.

Srikanth Karnati, Michael Seimetz, Florian Kleefeldt, Avinash Sonawane, Thati Madhusudhan, Akash Bachhuka, Djuro Kosanovic, Norbert Weissmann, Karsten Krüger, Süleyman Ergün

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05716984 (A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on the Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide in Improving Type 3 Pulmonary Hypertension.), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05716984 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on the Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide in Improving Type 3 Pulmonary Hypertension.

TypeinterventionalSponsorShengjing HospitalRan2023 to 2024Enrolled72ConditionsGroup 3 Pulmonary HypertensionArmsrecombinant human brain natriuretic peptide, Placebo
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Srikanth KarnatiInstitute of Anatomy and Cell Biology, Julius-Maximilians-University Würzburg, Würzburg, Germany.
Michael SeimetzExcellence Cluster Cardio-Pulmonary System (ECCPS), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany.
Florian KleefeldtInstitute of Anatomy and Cell Biology, Julius-Maximilians-University Würzburg, Würzburg, Germany.
Avinash SonawaneDepartment of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, India.
Thati MadhusudhanCenter for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany.
Akash BachhukaUniSA Science, Technology, Engineering and Mathematics, University of South Australia, Mawson Lakes Campus, Adelaide, SA, Australia.
Djuro KosanovicExcellence Cluster Cardio-Pulmonary System (ECCPS), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany.
Norbert WeissmannExcellence Cluster Cardio-Pulmonary System (ECCPS), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany.
Karsten KrügerDepartment of Exercise Physiology and Sports Therapy, University of Giessen, Giessen, Germany.
Süleyman ErgünInstitute of Anatomy and Cell Biology, Julius-Maximilians-University Würzburg, Würzburg, Germany.
University of Würzburg · DEUniversities of Giessen and Marburg Lung Center · DEGerman Center for Lung Research · DEGiessen School of Theology · DEIndian Institute of Technology Indore · INJohannes Gutenberg University Mainz · DEUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide and encompasses chronic bronchitis and emphysema. It has been shown that vascular wall remodeling and pulmonary hypertension (PH) can occur not only in patients with COPD but also in smokers with normal lung function, suggesting a causal role for vascular alterations in the development of emphysema. Mechanistically, abnormalities in the vasculature, such as inflammation, endothelial dysfunction, imbalances in cellular apoptosis/proliferation, and increased oxidative/nitrosative stress promote development of PH, cor pulmonale, and most probably pulmonary emphysema. Hypoxemia in the pulmonary chamber modulates the activation of key transcription factors and signaling cascades, which propagates inflammation and infiltration of neutrophils, resulting in vascular remodeling. Endothelial progenitor cells have angiogenesis capabilities, resulting in transdifferentiation of the smooth muscle cells

Indexed as

COPDemphysemahypoxiaoxidative stresspulmonary hypertension

Identifiers

PMID33912600
PMCPMC8072123
OpenAlexW3156223156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.